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Background. In this pilot observational 
study, we aimed to investigate the effect 
of preoperative magnesium infusion on 
laryngospasm frequency and other res-
piratory complications in children with 
respiratory findings undergoing esopha-
geal dilatation after the ingestion of caustic 
substances.
Methods. Sixty children between the ages 
of 2 and 12 scheduled for esophageal 
dilatation were divided into two groups: 
the magnesium group (Group M), which 
consisted of children with respiratory 
symptoms and who received IV 30 mg/
kg magnesium sulfate preoperatively, and 
the control group (Group C), who received 
the same volume of saline. Anesthesia was 
induced with fentanyl, propofol, and miva-
curium and maintained using a 60% N2O 
and 2-3% sevoflurane mixture in oxygen. 
Demographic and hemodynamic data, as 
well as the incidence of respiratory com-
plications (laryngospasm, bronchospasm, 
apnea, cough, and desaturation) during 
the perioperative period were recorded 
until the time of discharge from the recov-
ery room.
Results. Demographic data and hemody-
namics were similar in the two groups. 
The laryngospasm, bronchospasm, apnea, 
and cough incidences were also similar 
between the groups, although the desatu-
ration incidence was lower in Group M 
than in Group C (p=0.013). The number of 
complications in total was lower in Group 
M as well (p=0.008), although the number 
of children who experienced complica-
tions in each group was similar.
Conclusion. Prophylactic administration 
of 30 mg/kg of magnesium to children 
with respiratory symptoms may decrease 
the frequency of postoperative respiratory 
complications in children undergoing es-
ophageal dilatation.
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INTRODUCTION
Esophageal injury caused by caustic sub-
stances in children generally occurs af-
ter children accidentally drink cleaning 
agents. Although patient mortality is rare 
in these cases, morbidity is quite high. 
(1,2) The burns that occur after ingestion 
of caustic substances may lead to strictures 
in the esophagus in the weeks following 
ingestion. Treatment includes esophageal 
dilatation under general anesthesia. (3,4) 
In children with a stricture, aspiration 
because of dysphagia may cause chronic 
cough, productive cough, and frequent 
pulmonary infections. Furthermore, la-
ryngoscopy (used to place bougies) and 
tracheal stimulation from endotracheal 
tube movement during dilatation, as well 
as the esophageal dilatation itself, may 
cause respiratory complications during the 
perioperative period. (5)
According to the routine approach prac-
ticed in our clinic, (4) children who are 
treated at the hospital after ingesting caus-
tic substances are examined to assess the 
injury severity and the presence of perfora-
tion. If no edema hindering oral intake is 
detected in the oropharyngeal structures, 
the children are sent home, and a barium 
swallow is performed three weeks later. 
When esophageal strictures are detected, 
these strictures are dilated in three-week 
intervals.
Magnesium is used to treat hyperreac-
tive airway and asthma because it relaxes 
the smooth muscles of the bronchi. (6) 
Although magnesium has been shown to 
decrease the frequency of laryngospasm 
in children undergoing tonsillectomy, (7) 
its effect in other surgeries has not been 
studied. When one considers that respira-
tory complications are more frequent in 
children with respiratory tract problems, 
magnesium may be beneficial. In this pilot 
observational study we aimed to investi-
gate the effect of preoperative magnesium 
infusion on the frequency of laryngospasm 
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and other respiratory complications in 
children with pathological auscultation 
findings undergoing esophageal dilatation 
after the ingestion of caustic substances.
METHODS
In our clinic, children who are scheduled 
for esophageal dilatation are adminis-
tered a 1 mg/kg intravenous (IV) dose of 
methylprednisolone with 2 ml/kg/hour 
5% dextrose in a 0.2% NaCl infusion. If 
respiratory symptoms are revealed in the 
preoperative anesthesia examination (e.g., 
prolonged expirium, coarse or moist rales, 
cough, and productive cough), then ac-
cording to our departmental protocol, we 
administer magnesium infusion under 
monitored conditions in the premedica-
tion room, unless there are any contrain-
dications, such as neuromuscular junction 
diseases, kidney failure, cardiac conduc-
tion defects, and hypotension.
After approval had been obtained from 
the Clinical Research Ethics Committee 
(Nr: 2009/1921; Prof. Dr. Güher Saruhan 
Direskeneli), this prospective observa-
tional study enrolled 60 children between 
the ages of 2 and 12 years of age who were 
scheduled for elective esophageal dilata-
tion with bougies. Informed consent was 
obtained from the children’s parents. Chil-
dren with bronchial asthma, acute pul-
monary infection, or a contraindication 
for magnesium and/or bronchodilator 
treatment were excluded from this study. 
The same researcher (MSK) screened the 
children and prescribed the magnesium 
therapy. The patients were divided into 
two groups: the magnesium (Group M) 
and control groups (Group C). Children 
in Group C had no respiratory symptoms. 
The anesthesia, follow-up, and outcome 
assessments were performed by another 
researcher (HBO, TÖS), who were blind-
ed to the preoperative medication that was 
used.
After being transferred from the hospital 
ward to the premedication room, the pa-
tients were monitored with a pulse oxime-
ter (SpO2) and administered an IV dose 
of 0.1-0.15 mg/kg midazolam and 0.1 mg/
kg atropine. Group M received IV doses of 
30 mg/kg magnesium sulfate diluted with 
0.9% NaCl (total=25 ml in 15 minutes), 
with electrocardiography and non-inva-
sive blood pressure monitoring. Group C 
received the same volume of saline. The 
patients were then transferred to the oper-
ating room, and anesthesia was routinely 
induced with 1 µg/kg fentanyl, 2-3 mg/
kg propofol, and 0.25 mg/kg mivacurium. 
Following intubation, mechanical ven-
tilation was started with 6-8 ml/kg tidal 
volume. The inspiration to expiration ra-
tio was 1:2. The positive end expiratory 
pressure (PEEP) was 4 cm H2O, and the 
respiratory rate was set to maintain end-
tidal carbon dioxide (EtCO2) levels be-
tween 30 and 35 mmHg. Anesthesia was 
maintained using 60% N2O and 2-3% 
sevoflurane in oxygen. The anesthesia was 
discontinued at the end of surgery, and the 
oral and tracheal secretions were cleared. 
After determining that an adequate ven-
tilation rate and EtCO2 were maintained 
with spontaneous respiration within nor-
mal limits, the patients who were awake 
and had adequate muscle strength without 
bronchospasms received maximal inspira-
tory volume at the end of inspiration in the 
lateral decubitus position; then they were 
extubated. These children were monitored 
for three minutes while they were given 
high flow oxygen with a face mask. The 
children who did not have nasal flaring 
or desaturation (SpO2>92%) were trans-
ferred to the recovery room. During the 
recovery room follow-ups, the children 
who did not require treatment for respira-
tory complications, with SpO2≥96% on 
room air and modified Aldrete recovery 
scores9 points, were sent to the ward.
During anesthesia maintenance, the air-
way peak pressure was monitored in five-
minute intervals, and the highest value 
was recorded. The following periods were 
defined and recorded: the extubation peri-
od (the time anesthesia was discontinued 
until extubation), the extubation-recovery 
period (the time from extubation until the 
patient was transferred to the recovery 
room), and the duration that the patient 
remained in the recovery room (the time 
from entry to the recovery room until 
the patient fulfilled the recovery room 
discharge criteria). Laryngospasm, bron-
chospasm, apnea, cough, and desatura-
tion during the perioperative period were 
recorded as respiratory complications. 
Laryngospasm was diagnosed by wheez-
ing, stridor, increased respiration effort, 
decreased breath sounds, tracheal retrac-
tion, paradoxical movement of abdomen 
and thorax, difficulty in ventilation, and 
desaturation. Re-intubation was planned 
with IV administration of 1 mg/kg suc-
cinylcholine if saturation persisted below 
92% and did not increase after applying 
positive pressure ventilation therapy with 
100% O2. The presence of bilateral ex-
piratory wheezing, prolonged expirium, 
increased airway pressures, decreased 
breath sounds, shark fin appearance on 
the EtCO2 trace, and desaturation was 
diagnosed as bronchospasm. If bron-
chospasm was encountered in the perio-
perative period, the following treatment 
was planned: 100% O2 with manual bag 
ventilation, increased depth of anesthesia, 
and four to eight puffs of salbutamol with 
an metered-dose inhaler (MDI) (100 µg) 
spacer through an endotracheal tube at 20- 
to 30-minute intervals. The planned treat-
ment for bronchospasm that developed 
following extubation was 100% O2 (using 
a face mask), and 2.5-5 mg of salbutamol 
was administered with 20- to 30-minute-
breaks using a nebulizer. If the symptoms 
(refractory bronchospasm) continued, the 
IV administration of 1-10 µg/kg epineph-
rine was planned. Cessation of respiration 
for more than 30 seconds was described as 
apnea. A coughing episode was recorded 
if a patient experienced more than five 
coughs in a row. Desaturation was defined 
as SpO2<92%. The number of patients 
with complications and the total number 
of patients who experienced any of the 
five respiratory complications mentioned 
above were recorded for each group. Heart 
rate (HR) and systolic blood pressure 
(SBP) were recorded before infusion, at 
the end of infusion, after anesthesia in-
duction, following intubation, ten minutes 
after intubation, after extubation, and ten 
minutes after recovery room entry. Hypo-
tension was defined as a >30% decrease in 
the normal (by age) SBP value and was to 
be treated with an IV bolus of 2 ml/kg in 
0.9% NaCl. If hypotension persisted at the 
next measurement, the therapy was to be 
repeated. If hypotension occurred during 
anesthesia, the volatile anesthetic concen-
tration was to be decreased by 0.5%, and 
fluid infusion was planned. If the HR fell 
below the normal value for the patient’s 
age group, it was defined as bradycardia, 
and an administration of 0.2 mg/kg atro-
pine was planned for these patients. If the 
SpO2 level was >92% during bradycardia, 
ventilation with 100% O2 was planned; if 
it was sustained, then atropine was consid-
ered.
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STATISTICAL EVALUATION
To the best of our knowledge, no data have 
been recorded regarding the incidence of 
respiratory complications in children un-
dergoing esophageal dilatation. A study of 
the effect of magnesium infusion on the in-
cidence of laryngospasm in tonsillectomy 
cases reported that laryngospasm occurred 
in 25% of the control group patients and 
in 0% of the magnesium group patients. 
(7) A two-way sample size calculation 
(α=0.05 and β=0.2) with 25% incidence in 
the control group indicated that 30 people 
were needed in each group. The values are 
shown as median [minimum-maximum] 
and numbers (frequency %). The Mann-
Whitney-U test was used to compare each 
patient’s age, weight, peak pressure, extu-
bation duration, recovery duration, and to-
tal number of complications. The presence 
of complications was compared using the 
χ2 test. Blood pressure and heart rate data 
were compared within the groups with re-
peated measures ANOVA and between the 
groups using Student’s t test. P<0.05 was 
determined to be statistically significant.
RESULTS
All enrolled participants, with 30 patients 
in each group, completed the study and 
were included in the statistical analysis.
The groups were similar in terms of the 
patients’ ages, weights, and extubation du-
rations, but the highest peak pressure and 
recovery room duration were significantly 
lower in Group M than in Group C (table 
1). The laryngospasm, bronchospasm, ap-
nea, and coughing incidences were also 
similar between the groups, although the 
desaturation incidence of Group M was 
lower than that of Group C. The total num-
ber of complications was lower in Group 
M, although the number of children who 
experienced complications in each group 
was similar (table 2).
Thirteen patients who developed laryngo-
spasm following extubation were treated 
with positive pressured ventilation with 
100% O2. In Group C, two laryngospasm 
patients who were resistant to therapy were 
treated with IV 1 mg/kg succinylcholine. 
None of the patients required intubation. 
Two Group C patients who developed 
bronchospasm perioperatively were given 
100% O2 and six puffs of salbutamol with 
an MDI spacer; symptom improvement 
was observed after the first application. 
Seventeen children in Group C and ten 
children in Group M with SpO2<96% were 
given nebulized O2 in the recovery room.
No significant between-group or within-
group differences were detected in the 
hemodynamic data at the recorded time 
points (figures 1, 2). One patient in each 
group developed bradycardia in addi-
tion to laryngospasm; the bradycardia 
improved after the laryngospasm was 
treated. None of the patients experienced 
any hemodynamic problems that required 
treatment.
Figure 1. The heart rate (HR) pattern re-
corded at the measurement times.
PACU, Post Anesthesia Care Unit. 
Figure 2. The systolic blood pressure (SBP) 
values recorded at the measurement times. 
PACU, Post Anesthesia Care Unit.
DISCUSSION
In this study, we observed an increase in the 
frequency of respiratory complications in 
children with esophageal dilatation caused 
by stricture development following caustic 
substance ingestion. The preoperative IV 
administration of 30 mg/kg magnesium 
sulfate to patients with respiratory symp-
toms did not change the frequency of la-
ryngospasm but did decrease the frequency 
of perioperative desaturation and the total 
number of respiratory complications as 
well as reduce the peak airway pressures 
during mechanical ventilation.
Although chronic aspiration caused by 
esophageal atresia and gastroesophageal 
reflux is well known to trigger pneumo-
nia, chronic cough, and hyper-reactive 
airway, (8,9) there are no data concerning 
the perioperative respiratory complica-
tions of caustic ingestion. Caustic ingestion 
may cause esophageal strictures and inhibit 
peristaltic contractions; therefore, swallow-
ing problems can occur. Food and secretion 
aspirations and chronic micro-aspiration 
caused by reflux may be observed in these 
children. Respiratory complications during 
anesthesia, the most common of which are 
laryngospasm and bronchospasm, (10) are 
also well known to occur more frequently 
in children with airway problems. (11)
The frequency of laryngospasm caused by 
general anesthesia is increased in the pedi-
atric population compared with adults. 
(12) Particularly when there is a risk of 
inadequate depth of anesthesia (i.e., the 
induction and emergence period), foreign 
bodies, such as secretions, laryngoscope, 
tube, and catheters, can irritate the vocal 
cords and cause laryngospasm. The inci-
dence of laryngospasm may vary because 
of patient-related factors (e.g., upper res-
piratory infection, passive smoking, obe-
sity, and reflux) or the type of operation 
being performed. (13) Laryngospasm 
and upper respiratory tract complications 
caused by distal afferent esophageal nerve 
stimulation are observed more frequently 
in endoscopic procedures involving the 
esophagus. (14,15) Thus, children who 
undergo esophageal dilatation have both 
patient-related and operation-related risks 
of laryngospasm. In the literature, the inci-
dence of laryngospasm in general pediatric 
cases is 0.04-14% and as high as 21-27% in 
tonsillectomy patients. (5) To the best of 
our knowledge, there are no available data 
on the incidence of laryngospasm in chil-
dren undergoing esophageal dilatation. In 
our study, although the difference was not 
statistically significant, the laryngospasm 
incidence was lower in Group M than in 
Group C. If magnesium was ineffective, one 
would expect a higher incidence of laryn-
gospasm in Group M because of the pre-
operative respiratory system findings. This 
result can be explained by the preventive 
effect of the preoperative magnesium infu-
sion. Although lidocaine and other agents 
reportedly prevent laryngospasm, (5) the 
Gulhas et al. study is the only one that used 
magnesium to prevent laryngospasm in 
children. (7) Forty children undergoing ad-
enoidectomy and tonsillectomy were given 
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1 mg/kg lidocaine before intubation and 
15 mg/kg magnesium after intubation, and 
they were extubated under deep anesthesia. 
The Gulhas et al. study did not report air-
way pressures or complication (other than 
laryngospasm). Our study differs from the 
study by Gulhas et al. because of the lack 
of preventive lidocaine and higher magne-
sium doses. The laryngospasm incidence 
observed in Group C was greater than that 
in the control group in the Gulhas et al. 
study; this discrepancy may be attributed 
to the operation type and the fact that their 
patients were extubated under deep anes-
thesia. However, extubation under deep 
anesthesia in patients with a high risk of 
aspiration because of esophageal trauma 
would be unsafe.
Magnesium relaxes the smooth muscles by 
decreasing the intracellular Ca2+ level via 
Na+-Ca2+ pump activation. In children 
with moderate to severe asthma, 25-75 
mg/kg magnesium as an adjuvant leads to 
bronchodilatation, prevents inflammation 
development by mast-cell stabilization, 
(16) and decreases the peak pressures in 
treatment-resistant cases. (17) This bron-
chodilator effect of magnesium is likely also 
responsible for the lower peak airway pres-
sures observed in Group M in our study. 
Furthermore, magnesium potentiates opi-
oids and muscle relaxants, which may affect 
the depth of anesthesia, (18) contributing 
to the decrease in peak airway pressures.
Although the incidences of apnea, cough, 
and bronchospasm were not significantly 
different between the groups, there was a 
trend of a greater number of complications 
in Group C. A significantly increased fre-
quency of desaturation in the control group 
is also likely associated with the higher total 
number of complications in this group.
Similar extubation durations in both 
groups suggest that the depth of anesthesia 
was similar in both groups. Although the 
complication rate was greater in the control 
group, no significant between-group differ-
ence was observed for the extubation re-
covery period. The recovery room stay was 
significantly shorter in Group M. However, 
this five-minute difference may be the re-
sult of the decreased total number of com-
plications in Group M and is not clinically 
significant.
Regarding the hemodynamic findings, we 
did not observe any between-group differ-
ences. High doses of magnesium may be 
associated with hypotension, (19) and the 
lack of serum magnesium measurements 
can be criticized in our study. However, 
magnesium doses up to 75 mg/kg have 
been used in pediatric populations without 
any adverse events, similar to our study. 
(20)
The main limitation of this study is its 
lack of a randomized controlled design. 
We hypothesized that there would be an 
increased number of respiratory complica-
tions in the children with pathologic aus-
cultation findings. However, the decreased 
number of complications in Group M 
compared with the children without aus-
cultation findings confirms the assump-
tion that magnesium might prevent the 
respiratory complications that are associ-
ated with this surgery.
Our study limitations also include the lack 
of monitoring of the anesthesia depth and 
neuromuscular activity. Magnesium sul-
fate administered in 30-60 mg/kg doses 
during the induction of pregnant women 
with preeclampsia was shown to increase 
the duration of action of 0.15 mg/kg mi-
vacurium by 25 minutes. (21) We did not 
observe a delay in the extubation duration 
in Group M, likely because of the timing 
of the magnesium administration (20 min-
utes before induction).
To conclude, the administration of prophy-
lactic 30 mg/kg magnesium may decrease 
the frequency of postoperative respiratory 
complications in children with respiratory 
problems who are undergoing esophageal 
dilatation because of corrosive esophagitis. 
Further studies are required to design an 
ideal regimen in terms of the medication 
dose and administration protocol.
Table 1. Patient demographics in each group, the highest airway peak pressure values recorded during surgery, and the distribution of the 
durations that were compared between the groups.
Group M (n=30) Group K (n=30) P
Age 6 [2-12] 6.5 [2-12] 0.284
Weight (kg) 15.5 [8-31] 16.5 [9-32] 0,588
Peak airway pressure (cm H2O) 20.5 [15-28] 24 [13-36] 0.041
Anesthesia duration 40 [35-60] 37.5 [30-67] 0.313
Extubation period (min) 6 [5-15] 8 [5-20] 0.086
Extubation-recovery period (min) 6.5 [4-20] 7 [4-32] 0.277
Duration that the patient remained in the 
recovery room (min)
30 [25-50] 35 [25-80] 0.02
The values are shown as the median [minimum-maximum] and were compared with the Mann-Whitney U-test.
Table 2. The distribution of complications between groups, the number of patients with complications, and the total number of complications.
Group M (n=30) Group C (n=30) P
Laryngospasm (#) 3 (10%) 10 (33.3%) 0.057
Bronchospasm (#) 0 (0%) 2 (6.7%) 0,492
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Apnea (#) 7 (23.3%) 13 (43.3%) 0,1
Cough (#) 12 (40%) 18 (60%) 0,121
Desaturation (#) 6 (20%) 15 (50%) 0,013
Number of patients with complications (n) 
(#)
16 (53.3%) 24 (80%) 0.054
Total number of complications ( ) 1[0-3] 2 [0-5] 0.008
Values are given as the number (% frequency) or median [minimum- maximum]. #: the data were compared with the χ2 test.  : the data 
were compared with the Mann-Whitney U-test.
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